Compare Natera Inc. Common Stock (NTRA) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Ultra Short Bond ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Natera Inc. Common Stock is far larger — about 5.6× Vanguard Ultra Short Bond ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Ultra Short Bond ETF for 64 Days on average.
| NTRA | VUSB | |
|---|---|---|
Market Cap | $57.03B | $10.20B |
Volume | 1,131,157 | 1,227,697 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $50.03 |
52-Week Low | $179.42 | $49.41 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VUSB is trading at $49.475, showing minimal daily movement with a slight decline of 0.01%. Technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The ETF maintains consistent dividend distributions, with recent payments of $0.17-0.18 per share. Market sentiment is influenced by Federal Reserve interest rate expectations, positioning short-term bond ETFs favorably amid potential rate increases.
The outlook for VUSB remains cautious due to bearish technical signals and interest rate sensitivity. Investment opportunity exists for investors seeking short-term bond exposure with regular income, though risks include Fed policy shifts and market volatility. The ETF's stability and dividend consistency provide defensive characteristics in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
